Novan, Inc. (NASDAQ: NOVN) will participate in the Virtual Investor Innovation in Dermatology Spotlight event on Tuesday, April 26.
For the event, CEO Paula Brown Stafford will be joined by John A. Donofrio, Novan’s Executive Vice President and Chief Operating Officer.
The event will spotlight Novan’s newly acquired portfolio of commercial medical dermatology products and its proprietary nitric oxide-based technology platform, NITRICIL™, which has the potential to generate new, innovative treatments for multiple dermatological indications.
Novan recently announced its acquisition of EPI Health, a growing specialty dermatology company that has launched and markets innovative prescription therapies to dermatologists to improve the quality of life of patients. As a result, Novan now has a well-established product portfolio that addresses patient needs across psoriasis, rosacea, dermatosis and acne.
Novan’s innovative and clinically proven NITRICIL™ technology leverages nitric oxide’s (NO) naturally occurring antimicrobial and immunomodulatory effects to develop potential new therapies for unmet medical needs across multiple therapeutic areas. NITRICIL stores the gaseous NO species on large polymers, which allows nitric oxide to be applied as timed-release chemical entities.
This technology allows the Company to control the level of nitric oxide storage, the rate of release, and the molecule size for targeted delivery. This targeted technology with anti-microbial and anti-inflammatory properties has the potential to address a number of skin diseases.
NOVN shares dipped eight cents, or 2.4%, to $3.04.